---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-055005"
form_type: "8-K"
ticker: "RANI"
cik: "0001856725"
company_name: "Rani Therapeutics Holdings, Inc."
filed_at: "2023-10-25T23:59:59+00:00"
generated_at: "2026-06-09T11:43:29.676962+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Rani Therapeutics reports positive preclinical safety data for RaniPill capsule in 60-day GLP study

## Summary
- 60-day repeat administration in healthy animals showed no treatment-related adverse events; all animals remained healthy.
- Study evaluated RT-100 (RaniPill with mannitol) vs. mock capsule; supports safety for clinical trials.
- Data enable launch of longer-term trials including Phase II study of RT-102 for osteoporosis planned for 2023.
- RaniPill platform is drug-agnostic, aiming to replace injections for biologics.

## SEC filing metadata
- accession: 0000950170-23-055005
- form_type: 8-K
- ticker: RANI
- cik: 0001856725
- company_name: Rani Therapeutics Holdings, Inc.
- filed_at: 2023-10-25T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1856725/000095017023055005/0000950170-23-055005-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1856725/000095017023055005/rani-20231025.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-055005
- JSON: https://secwatch.observer/filing/0000950170-23-055005.json
- Plain text: https://secwatch.observer/filing/0000950170-23-055005.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.